A novel agent effective against Clostridium difficile infection

  • Antimicrob Agents Chemother. 2012 Mar;56(3):1624-6. doi: 10.1128/AAC.06097-11.
Sofya Dvoskin  1 ,  Wei-Chu Xu ,  Neal C Brown ,  Ivan B Yanachkov ,  Milka Yanachkova ,  George E Wright
Affiliations
  • 1. GLSynthesis, Inc Worcester, Massachusetts, USA.
PMID: 22203600 DOI: 10.1128/AAC.06097-11
Abstract

N(2)-(3,4-Dichlorobenzyl)-7-(2-[1-morpholinyl]ethyl)guanine (MorE-DCBG, 362E) is a synthetic purine that selectively inhibits the replication-specific DNA Polymerase of Clostridium difficile. MorE-DCBG and its analogs strongly inhibited the growth of a wide variety of C. difficile strains. When administered orally in a hamster model of C. difficile-specific colitis, 362E was as effective as oral vancomycin, the current agent of choice for treating severe forms of the human disease.

Products